pharmaceutical-investing Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
pharmaceutical-investing Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound